Project Grant K08HL181183
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$165K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Davis, CA, USA
Similar Awards
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $114,594.00 to the University of Virginia to conduct research on the regulation of pituitary-adenylate cyclase activating peptide (PACAP) expression and its role in protecting early neonatal respiration. The research aims to investigate whether PACAP is necessary for establishing and protecting stable respiratory rhythmogenesis in neonates, as well as the mechanisms...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the VPS34 protein in the development and progression of pulmonary arterial hypertension (PAH). The $491,056.01 award, effective May 20, 2025 through April 30, 2028, aims to examine the regulation and function of VPS34 in PAH, determine its impact on proliferation and survival of pulmonary artery...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA 93.837 - Cardiovascular Diseases Research, provides $1,480,392 to Case Western Reserve University (CWRU) to conduct research on the adverse effects of neonatal continuous positive airway pressure (CPAP) on lung development. The research aims to investigate the mechanosensitive pathways, including the Piezo family of mechanosensors, extracellular matrix, and plasma membrane caveolae, that contribute to...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on enhancing the efficiency of generating human vasculature in a gene-edited pig. The $279,750 award, granted on May 25, 2025, aims to compare the grantee's proven approach using somatic cell nuclear transfer (SCNT) with an alternative approach using in vitro fertilization, zygote gene editing, and blastocyst complementation. The goal...
This $102,932 federal Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify clinically accessible metrics that can serve as surrogates for right ventricular-pulmonary arterial (RV-PA) coupling and indicators of RV adaptation in pulmonary arterial hypertension (PAH). The proposed research aims to: 1) develop a multivariable model to identify clinically available metrics as...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, provides $249,000.00 in funding to Texas A&M University System Health Science Center to conduct research on the regulation of vasopressin neurons in a rodent model of heart failure. The key goals of the research are to investigate how vasopressin neurons self-regulate their excitability and paracrine release of vasopressin, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,940 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) with a project period from Sep 20, 2024 to Aug 31, 2029. The grant aims to develop a novel mouse model of flow-induced pulmonary hypertension (PH) that better represents the physiological conditions observed in patients with congenital heart disease. Additionally, the project...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA Program 93.837 - Cardiovascular Diseases Research provides $776,754 to conduct a longitudinal neurodevelopmental (ND) outcomes study, titled the "COMPASS ANCILLARY NEURODEVELOPMENTAL OUTCOMES (CAN-DO)" study. The study aims to compare ND outcomes at 36 months of age between neonates with ductal-dependent pulmonary blood flow who underwent either surgical systemic-to-pulmonary artery...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $596,809 to Emory University to conduct research on the role of the mitochondrial protein MitoNEET in pulmonary hypertension (PH). The research aims to elucidate how MitoNEET regulates pulmonary artery smooth muscle cell function and mitochondrial bioenergetics, and to evaluate the potential of MitoNEET ligands as novel therapies for group 3 PH,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $522,794 to the University of Illinois to conduct research on the role of the voltage-gated proton channel HV1 in the development of pulmonary hypertension. The project aims to use transgenic mice and in vivo approaches to delineate HV1's contributions to pulmonary hypertension pathogenesis, examine the molecular mechanisms, and...